ArticleGenes & diseases2027
Identification of platelet-derived biomarker in a cohort of Parkinson's disease.
Article in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence has suggested that platelets (PLTs) share biochemical properties with neurons. However, whether PLTs might serve as biomarkers of Parkinson's disease (PD) remains uncertain. In this study, we first analyzed RNA data from a publicly available microarray of the substantia nigra (SN) and RNA-seq data from the PLTs of newly recruited PD patients using weighted gene coexpression network analysis (WGCNA). We found that in the SN, the majority of network modules were associated with chromatin organization, energy metabolism, and synaptic signaling, whereas those in the PLTs were related to chromatin organization and DNA metabolism. Potential PLT biomarkers were then screened by comparing the differentially expressed genes (DEGs) in the significant module pathways with those identified in the SN data by microarray. Additionally, significant genes were identified using genome-wide association study (GWAS) and transcriptome-wide association study (TWAS). The resulting 20 candidate genes were further tested for consistency in single-cell RNA-seq data, followed by assessment using receiver operating characteristic curve (ROC) analysis and qPCR validation. The combination of the CRLF3 and LRRC37A2 genes exhibited the best diagnostic performance. Collectively, both PLTs and the SN were common in the chromatin organization pathway, and the diagnostic value of PLT-derived CRLF3 and LRRC37A2 genes deserves further large-scale studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.